Research progress of programmed death 1 immune-targeted therapy for B-cell lymphoma
10.3760/cma.j.issn.1009-9921.2016.01.013
- VernacularTitle:程序性死亡分子1免疫治疗在B细胞淋巴瘤中的研究进展
- Author:
Li LIN
;
Ling LI
;
Xudong ZHANG
;
Zhaoming LI
;
Mingzhi ZHANG
;
Qingjiang CHEN
- Publication Type:Journal Article
- Keywords:
Lymphoma;
B-cell;
Immunotherapy;
Molecular targeted therapy;
Programmed death 1;
Programmed death 1 ligand
- From:
Journal of Leukemia & Lymphoma
2016;25(1):45-48,56
- CountryChina
- Language:Chinese
-
Abstract:
The inhibitors of programmed death 1 (PD-1)/PD-1 ligand (PD-L1) become a highlight in tumor immunotherapy and provide a new direction for immune-targeted therapy for cancer. More and more studies have confirmed that PD-1/PD-L1 inhibitors could improve effects and be well-tolerated. Early clinical trials of PD-1 inhibitors have shown significant clinical efficacy in various solid tumours. The unique role of the PD-1 pathway in lymphoma has been found gradually. This article summarized the advancement of PD-1 in B-cell lymphoma therapy.
